V3 Biotechnologies Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.67 M
- Company Age 20 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth %
- Profit Growth -9.35%
- Ebitda 63.82%
- Net Worth -0.14%
- Total Assets -0.08%
About V3 Biotechnologies
V3 Biotechnologies Private Limited (VBPL) is a Private Limited Indian Non-Government Company incorporated in India on 18 August 2004 and has a history of 20 years and five months. Its registered office is in Kolkata, West Bengal, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.67 M, as per Ministry of Corporate Affairs (MCA) records.
Anurag Sonthalia and Ajit Agrawal serve as directors at the Company.
Company Details
-
Location
Kolkata, West Bengal, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24239WB2004PTC099487
-
Company No.
099487
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
18 Aug 2004
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Kolkata
Industry
Who are the key members and board of directors at V3 Biotechnologies?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anurag Sonthalia
|
Additional Director | 12-Apr-2024 | Current |
|
Ajit Agrawal
|
Additional Director | 11-Feb-2022 | Current |
Financial Performance of V3 Biotechnologies.
V3 Biotechnologies Private Limited, for the financial year ended 2020, experienced no change in revenue, with a 0% increase. The company also saw a slight decrease in profitability, with a 9.35% decrease in profit. The company's net worth dipped by a decrease of 0.14%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of V3 Biotechnologies?
In 2019, V3 Biotechnologies had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
V3 International LimitedAnurag Sonthalia and Ajit Agrawal are mutual person
-
Bio-Caps India LimitedAnurag Sonthalia and Ajit Agrawal are mutual person
-
Vaibhav Laxmi Chemicals Private LimitedAnurag Sonthalia is a mutual person
-
Ruchika Trades Pvt Ltd
Anurag Sonthalia is a mutual person
-
Vishnudham Distributors Private Limited
Anurag Sonthalia is a mutual person
-
Sri Vishwanath Traders Private Limited
Anurag Sonthalia is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at V3 Biotechnologies?
Unlock and access historical data on people associated with V3 Biotechnologies, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of V3 Biotechnologies, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped V3 Biotechnologies's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
